UNG (Uracil-DNA glycosylase) variants and mutations
UNG (also known as Uracil-DNA glycosylase) is a human protein-coding gene encoding an uracil-DNA glycosylase protein. It removes uracil from DNA and initiates base-excision repair, protecting the genome from cytosine deamination and misincorporated uracil. Biallelic loss-of-function variants can cause hyper-IgM syndrome through defective antibody class-switch recombination. This analysis covers 618 UNG variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes hyper-IgM syndrome type 5, food allergy, and Hereditary breast and ovarian cancer syndrome. Example UNG variants include I2I, G3A, and G3S.
Variant analysis overview
- Gene: UNG
- Protein: Uracil-DNA glycosylase
- UniProt accession: P13051
- Organism: Homo sapiens
- Variants analyzed: 618
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 378 unspecified-consequence records; 77 synonymous variants; 124 missense variants; 7 in-frame deletions; 8 stop-gained variants; 20 frameshift variants; 1 in-frame insertions; 1 splice-region variants; 2 substitution
- Prediction scores: 534 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyper-IgM syndrome type 5, food allergy, Hereditary breast and ovarian cancer syndrome, hereditary breast ovarian cancer syndrome, neoplasm, infection, cancer, lymphoma, common variable immunodeficiency, BENTA disease, activated PI3K-delta syndrome, immunodeficiency, common variable, 7.
Protein structure and variant hotspots
- Protein features: 11 binding sites; 6 post-translational modification sites.
- PTM context: 21 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable UNG variants
Examples include I2I, G3A, G3S, G3C, G3D, G3G, G3V, G3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- I2I (p.Ile2Ile), rs886048905, gnomAD 12-109097685-C-A, CADD 13.60
- G3A (p.Gly3Ala), Ensembl rs2042140508
- G3S (p.Gly3Ser), ExAC rs781643146, gnomAD rs781643146, REVEL 0.19, CADD 24.20
- G3C (p.Gly3Cys), gnomAD 12-109097686-G-T, REVEL 0.51, CADD 32.00
- G3D (p.Gly3Asp), gnomAD 12-109097687-G-A, REVEL 0.41, CADD 29.70
- G3G (p.Gly3Gly), gnomAD 12-109097688-C-A, CADD 15.20
- G3V (p.Gly3Val), rs557013044, gnomAD 12-109098331-G-T, CADD 15.30
- G3R (p.Gly3Arg), gnomAD 12-109098345-G-C, CADD 5.51
- Q4K (p.Gln4Lys), Ensembl rs868596879
- Q4R (p.Gln4Arg), rs7488798, UniProt VAR 052697, gnomAD rs7488798, REVEL 0.17, CADD 28.20
- K5N (p.Lys5Asn), gnomAD rs2042140632, REVEL 0.11, CADD 26.40
- K5R (p.Lys5Arg), rs2135880926, ClinGen CA386468495, ClinVar RCV001368796, Ensembl rs2135880926, AlphaMissense 0.10, MetaLR 0.15, Uncertain significance, Hyper-IgM syndrome type 5
- K5T (p.Lys5Thr), gnomAD 12-109097693-A-C, REVEL 0.22, CADD 24.70
- T6A (p.Thr6Ala), rs2135880934, ClinGen CA386468500, ClinVar RCV002261948, Ensembl rs2135880934, REVEL 0.14, CADD 24.50, Uncertain significance, not provided
- T6M (p.Thr6Met), TOPMed rs990883898, gnomAD rs990883898, REVEL 0.17, CADD 26.80
- T6R (p.Thr6Arg), TOPMed rs990883898, gnomAD rs990883898, REVEL 0.23, CADD 22.90
- T6K (p.Thr6Lys), gnomAD 12-109097696-C-A, REVEL 0.16, CADD 22.20
- T6T (p.Thr6Thr), rs1236310377, gnomAD 12-109097697-G-T, CADD 4.67
- T17del (p.Thr17del), gnomAD 12-109098373-GGAC, CADD 7.81
- T6P (p.Thr6Pro), gnomAD 12-109098375-A-C, CADD 9.62
- L7I (p.Leu7Ile), gnomAD 12-109097698-C-A, REVEL 0.05, CADD 17.00
- L7L (p.Leu7Leu), gnomAD 12-109097700-C-A, CADD 10.80
- L7F (p.Leu7Phe), gnomAD 12-109098342-C-T, CADD 4.54
- L7W (p.Leu7Trp), rs764794281, gnomAD 12-109098351-TG-T, CADD 3.33
- L7M (p.Leu7Met), gnomAD 12-109098369-C-A, CADD 7.31
- L7P (p.Leu7Pro), rs765866952, gnomAD 12-109098399-CT-C, CADD 0.61
- L7E (p.Leu7Glu), rs2042149510, gnomAD 12-109098401-CTT-, CADD 5.21
- L7* (p.Leu7Ter), gnomAD 12-109098403-T-A, CADD 7.99
- L7V (p.Leu7Val), rs368919428, gnomAD 12-109098411-C-G, CADD 5.68, SIFT 0.38
- Y8C (p.Tyr8Cys), TOPMed rs1215646041, gnomAD rs1215646041, REVEL 0.25, CADD 24.00
- Y8H (p.Tyr8His), gnomAD 12-109097701-T-C, REVEL 0.09, CADD 22.10
- Y8F (p.Tyr8Phe), gnomAD 12-109097702-A-T, REVEL 0.21, CADD 22.50
- Y8* (p.Tyr8Ter), gnomAD 12-109097703-C-G, CADD 37.00
- Y8Y (p.Tyr8Tyr), gnomAD 12-109097703-C-T, CADD 13.50
- S9F (p.Ser9Phe), TOPMed rs2042140757
- S9del (p.Ser9del), gnomAD 12-109097702-ACTC, CADD 20.60
- S9S (p.Ser9Ser), gnomAD 12-109097706-C-T, CADD 11.80
- F10V (p.Phe10Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F10L (p.Phe10Leu), gnomAD 12-109097707-T-C, REVEL 0.37, CADD 29.80
- F10I (p.Phe10Ile), gnomAD 12-109097707-T-A, REVEL 0.50, CADD 28.80
- F10F (p.Phe10Phe), rs1446742630, gnomAD 12-109098338-C-T, CADD 2.10
- F11L (p.Phe11Leu), TOPMed rs1184960394, gnomAD rs1184960394, REVEL 0.28, CADD 24.80
- F11S (p.Phe11Ser), rs747684225, ClinGen CA6772435, ClinVar RCV001218242, ClinVar RCV004034062, REVEL 0.48, CADD 29.90, Uncertain significance, not specified; Hyper-IgM syndrome type 5
- S12F (p.Ser12Phe), gnomAD rs1448832810, REVEL 0.22, CADD 25.20, Uncertain significance, Hyper-IgM syndrome type 5
- S12P (p.Ser12Pro), ExAC rs769496984, TOPMed rs769496984, gnomAD rs769496984, REVEL 0.19, CADD 22.70, Uncertain significance
- S12T (p.Ser12Thr), rs769496984, ClinGen CA386468587, ClinVar RCV001883111, ClinVar RCV006327316, REVEL 0.09, CADD 18.00, Uncertain significance, not specified; Hyper-IgM syndrome type 5
- S12Y (p.Ser12Tyr), gnomAD 12-109097714-C-A, REVEL 0.19, CADD 24.60
- S12S (p.Ser12Ser), rs772832695, gnomAD 12-109097715-C-A, CADD 10.70
- P13H (p.Pro13His), NCI-TCGA Cosmic COSV9965, REVEL 0.13, CADD 23.60, Variant assessed as somatic; moderate impact.
- P13R (p.Pro13Arg), 1000Genomes rs572847021, REVEL 0.07, CADD 18.90
- P13S (p.Pro13Ser), gnomAD 12-109097716-C-T, REVEL 0.03, CADD 14.40
- P13P (p.Pro13Pro), gnomAD 12-109097718-C-A, CADD 4.50
- P13T (p.Pro13Thr), gnomAD 12-109098348-C-A, CADD 7.05
- P13L (p.Pro13Leu), rs921244212, gnomAD 12-109098349-C-T, CADD 0.96
- P13Q (p.Pro13Gln), gnomAD 12-109098349-C-A, CADD 0.72
- S14A (p.Ser14Ala), rs2499976292, ClinGen CA2580085749, ClinVar RCV003002484, Pathogenic
- S14N (p.Ser14Asn), Ensembl rs2042141019, REVEL 0.07, CADD 3.86
- S14I (p.Ser14Ile), gnomAD 12-109097720-G-T, REVEL 0.03, CADD 8.07
- S14S (p.Ser14Ser), gnomAD 12-109097721-C-T, CADD 12.10
- S14R (p.Ser14Arg), gnomAD 12-109097721-C-A, REVEL 0.07, CADD 14.70
- P15P (p.Pro15Pro), gnomAD 12-109097724-C-A, CADD 11.80
- P15A (p.Pro15Ala), gnomAD 12-109098378-C-G, CADD 3.85
- P15H (p.Pro15His), gnomAD 12-109098379-C-A, CADD 9.38
- P15L (p.Pro15Leu), rs1372884831, gnomAD 12-109098379-C-T, CADD 10.00
- A16S (p.Ala16Ser), TOPMed rs1171393436, gnomAD rs1171393436, REVEL 0.06, CADD 11.40
- A16T (p.Ala16Thr), NCI-TCGA Cosmic COSV5435, REVEL 0.03, CADD 14.20, Variant assessed as somatic; moderate impact.
- p.Ala16 Pro24del, rs1426059529, gnomAD 12-109097713-TCCC, CADD 21.30
- A16D (p.Ala16Asp), gnomAD 12-109097726-C-A, REVEL 0.06, CADD 16.90
- A16V (p.Ala16Val), gnomAD 12-109097726-C-T, REVEL 0.05, CADD 16.10
- A16A (p.Ala16Ala), gnomAD 12-109097727-C-G, CADD 10.70
- R17G (p.Arg17Gly), gnomAD 12-109097728-A-G, REVEL 0.18, CADD 9.30
- R17W (p.Arg17Trp), gnomAD 12-109097728-A-T, REVEL 0.18, CADD 18.00
- R17R (p.Arg17Arg), rs2042141244, gnomAD 12-109097730-G-A, CADD 13.80
- R17L (p.Arg17Leu), gnomAD 12-109098364-G-T, CADD 11.40
- R17Q (p.Arg17Gln), rs1438461547, gnomAD 12-109098364-G-A, CADD 12.00
- R17P (p.Arg17Pro), gnomAD 12-109098373-G-C, CADD 2.99
- K18R (p.Lys18Arg), gnomAD rs1358864015, REVEL 0.08, CADD 20.40
- K18K (p.Lys18Lys), rs1468280306, gnomAD 12-109097733-G-A, CADD 12.70
- K18E (p.Lys18Glu), rs753209535, gnomAD 12-109098384-A-G, CADD 0.83
- R19* (p.Arg19Ter), gnomAD rs1338829405, CADD 37.00
- R19R (p.Arg19Arg), gnomAD 12-109097734-C-A, CADD 14.00
- R19L (p.Arg19Leu), gnomAD 12-109097735-G-T, REVEL 0.09, CADD 23.50
- R19Q (p.Arg19Gln), gnomAD 12-109097735-G-A, REVEL 0.10, CADD 28.10
- R19C (p.Arg19Cys), rs754312331, gnomAD 12-109098408-C-T, CADD 10.40, SIFT 0.07
- R19S (p.Arg19Ser), gnomAD 12-109098408-C-A, CADD 9.80, SIFT 0.47
- R19G (p.Arg19Gly), rs754312331, gnomAD 12-109098408-C-G, CADD 9.98, SIFT 0.40
- R19H (p.Arg19His), rs1378670251, gnomAD 12-109098409-G-A, CADD 11.70, SIFT 0.09
- H20Q (p.His20Gln), ExAC rs770972381, gnomAD rs770972381, REVEL 0.11, CADD 2.31
- H20H (p.His20His), gnomAD 12-109097739-C-T, CADD 3.10
- H20G (p.His20Gly), rs751581970, gnomAD 12-109098418-G-GG, CADD 15.20
- H20P (p.His20Pro), gnomAD 12-109098421-A-AC, CADD 13.10
- H20Y (p.His20Tyr), rs1593318701, gnomAD 12-109098423-C-T, CADD 9.15, SIFT 1.00
- H20N (p.His20Asn), gnomAD 12-109098423-C-A, CADD 8.60, SIFT 0.60
- H20R (p.His20Arg), rs757878186, gnomAD 12-109098424-A-G, CADD 7.21, SIFT 0.66
- A21G (p.Ala21Gly), TOPMed rs1268732277, gnomAD rs1268732277, REVEL 0.04, CADD 12.90, Uncertain significance
- A21P (p.Ala21Pro), TOPMed rs1435043915, gnomAD rs1435043915, REVEL 0.06, CADD 1.93, Uncertain significance
- A21T (p.Ala21Thr), rs1435043915, ClinGen CA386468690, ClinVar RCV000797528, ClinVar RCV004027600, REVEL 0.03, CADD 0.43, Uncertain significance, Hyper-IgM syndrome type 5; not specified
- A21V (p.Ala21Val), rs1268732277, ClinGen CA386468699, ClinVar RCV001870777, TOPMed rs1268732277, REVEL 0.05, CADD 13.10, Uncertain significance, Hyper-IgM syndrome type 5
- P22A (p.Pro22Ala), ExAC rs774385200, TOPMed rs774385200, gnomAD rs774385200, REVEL 0.07, CADD 0.28
- P22L (p.Pro22Leu), rs373668102, ClinGen CA6772441, ClinVar RCV001109467, ESP rs373668102, REVEL 0.08, CADD 8.10, Uncertain significance, Hyper-IgM syndrome type 5
- P22S (p.Pro22Ser), ExAC rs774385200, TOPMed rs774385200, gnomAD rs774385200, CADD 5.35
- P22T (p.Pro22Thr), ExAC rs774385200, TOPMed rs774385200, gnomAD rs774385200, REVEL 0.05, CADD 0.76
- P22H (p.Pro22His), gnomAD 12-109097744-C-A, REVEL 0.10, CADD 8.36
- P22P (p.Pro22Pro), gnomAD 12-109097745-C-A, CADD 9.48
- P22R (p.Pro22Arg), gnomAD 12-109098391-C-G, CADD 5.33
- P22Q (p.Pro22Gln), gnomAD 12-109098391-C-A, CADD 5.14
- S23G (p.Ser23Gly), TOPMed rs2042141526
- S23R (p.Ser23Arg), TOPMed rs2042141526, REVEL 0.14, CADD 22.80
- S23A (p.Ser23Ala), gnomAD 12-109097740-GC-G, CADD 19.80
- S23S (p.Ser23Ser), gnomAD 12-109097748-C-T, CADD 9.51
- P24S (p.Pro24Ser), ExAC rs767154683, gnomAD rs767154683, REVEL 0.06, CADD 16.50
- P24R (p.Pro24Arg), gnomAD 12-109097745-CAGC, CADD 25.50
- P24T (p.Pro24Thr), gnomAD 12-109097749-C-A, REVEL 0.04, CADD 15.60
- P24H (p.Pro24His), gnomAD 12-109097750-C-A, REVEL 0.07, CADD 22.70
- P24P (p.Pro24Pro), gnomAD 12-109097751-C-T, CADD 7.77
- E25V (p.Glu25Val), Ensembl rs1593318054
- E25A (p.Glu25Ala), rs1376076211, gnomAD 12-109097751-CGA-, CADD 25.10
- E25K (p.Glu25Lys), gnomAD 12-109097752-G-A, REVEL 0.11, CADD 21.60
- E25D (p.Glu25Asp), gnomAD 12-109097754-G-T, REVEL 0.05, CADD 16.90
- P26L (p.Pro26Leu), ExAC rs775369845, gnomAD rs775369845, REVEL 0.05, AlphaMissense 0.07, Uncertain significance
- P26Q (p.Pro26Gln), rs775369845, ClinGen CA386468754, ClinVar RCV002755624, ExAC rs775369845, AlphaMissense 0.07, MetaLR 0.13, Uncertain significance, Hyper-IgM syndrome type 5
- P26S (p.Pro26Ser), rs1321029062, ClinGen CA386468752, ClinVar RCV001926775, gnomAD rs1321029062, REVEL 0.07, CADD 16.80, Uncertain significance, Hyper-IgM syndrome type 5
- P26T (p.Pro26Thr), gnomAD 12-109097755-C-A, REVEL 0.05, CADD 16.10
- P26P (p.Pro26Pro), rs2042141826, gnomAD 12-109097757-G-C, CADD 8.62
- p.Pro26 Ala27insGluGlyHis, rs1309243585, gnomAD 12-109097757-G-GG, CADD 15.70
- A27G (p.Ala27Gly), rs1390195003, gnomAD 12-109097756-C-CA, CADD 24.50
- A27T (p.Ala27Thr), gnomAD 12-109097758-G-A, REVEL 0.06, CADD 18.00
- A27S (p.Ala27Ser), gnomAD 12-109097758-G-T, REVEL 0.05, CADD 15.80
- A27V (p.Ala27Val), gnomAD 12-109097759-C-T, REVEL 0.05, CADD 12.90
- A27A (p.Ala27Ala), rs761928219, gnomAD 12-109097760-C-T, CADD 2.69
- V28I (p.Val28Ile), TOPMed rs2042141932, REVEL 0.04, CADD 6.38
- V28A (p.Val28Ala), gnomAD 12-109097762-T-C, REVEL 0.12, CADD 1.59
- V28V (p.Val28Val), rs2042141964, gnomAD 12-109097763-C-A, CADD 6.68
- Q29H (p.Gln29His), ExAC rs750472259, TOPMed rs750472259, gnomAD rs750472259, REVEL 0.04, CADD 10.50
- Q29P (p.Gln29Pro), rs765512122, ClinGen CA6772445, ClinVar RCV001109468, ExAC rs765512122, REVEL 0.03, CADD 0.11, Uncertain significance, Hyper-IgM syndrome type 5
- Q29R (p.Gln29Arg), ExAC rs765512122, TOPMed rs765512122, gnomAD rs765512122, REVEL 0.01, CADD 0.33, Uncertain significance
- Q29K (p.Gln29Lys), gnomAD 12-109097764-C-A, REVEL 0.03, CADD 3.29
- Q29E (p.Gln29Glu), gnomAD 12-109097764-C-G, REVEL 0.04, CADD 1.32
- Q29Q (p.Gln29Gln), rs750472259, gnomAD 12-109097766-G-A, CADD 4.87
- G30E (p.Gly30Glu), 1000Genomes rs534071307, ExAC rs534071307, TOPMed rs534071307, gnomAD rs534071307, REVEL 0.08, CADD 15.60
- G30R (p.Gly30Arg), gnomAD 12-109097767-G-C, REVEL 0.04, CADD 14.10
- G30W (p.Gly30Trp), gnomAD 12-109097767-G-T, REVEL 0.07, CADD 19.20
- G30G (p.Gly30Gly), rs766467977, gnomAD 12-109097769-G-T, CADD 8.69
- G30V (p.Gly30Val), rs868450528, gnomAD 12-109098382-G-T, CADD 8.35
- T31P (p.Thr31Pro), gnomAD 12-109097765-AG-A, CADD 19.60
- T31I (p.Thr31Ile), gnomAD 12-109097771-C-T, REVEL 0.02, CADD 12.50
- T31T (p.Thr31Thr), rs904612774, gnomAD 12-109097772-C-T, CADD 5.76
- G32S (p.Gly32Ser), TOPMed rs1593318088, gnomAD rs1593318088, REVEL 0.04, CADD 15.90
- G32C (p.Gly32Cys), gnomAD 12-109097773-G-T, REVEL 0.10, CADD 22.20
- G32R (p.Gly32Arg), gnomAD 12-109097773-G-C, REVEL 0.06, CADD 17.60
- G32G (p.Gly32Gly), gnomAD 12-109097775-C-T, CADD 9.29
- V33M (p.Val33Met), ExAC rs751970160, gnomAD rs751970160, REVEL 0.07, CADD 17.60
- V33L (p.Val33Leu), gnomAD 12-109097776-G-C, REVEL 0.04, CADD 15.80
- V33V (p.Val33Val), gnomAD 12-109097778-G-T, CADD 7.83
- A34T (p.Ala34Thr), rs886048906, ClinGen CA10636316, ClinVar RCV000299867, TOPMed rs886048906, AlphaMissense 0.07, MetaLR 0.16, Uncertain significance, Hyper-IgM syndrome type 5
- A34P (p.Ala34Pro), gnomAD 12-109097779-G-C, REVEL 0.06, CADD 22.40
- A34S (p.Ala34Ser), gnomAD 12-109097779-G-T, REVEL 0.05, CADD 16.80
- A34D (p.Ala34Asp), gnomAD 12-109097780-C-A, REVEL 0.05, CADD 6.61
- A34A (p.Ala34Ala), rs755512741, gnomAD 12-109097781-T-C, CADD 3.80
- G35E (p.Gly35Glu), TOPMed rs1479809103
- G35R (p.Gly35Arg), gnomAD 12-109097782-G-A, REVEL 0.11, CADD 11.60
- G35W (p.Gly35Trp), gnomAD 12-109097782-G-T, REVEL 0.09, CADD 17.90
- G35V (p.Gly35Val), gnomAD 12-109097783-G-T, REVEL 0.09, CADD 7.46
- G35G (p.Gly35Gly), rs781349708, gnomAD 12-109097784-G-A, CADD 1.38
- V36G (p.Val36Gly), Ensembl rs894993490
- V36L (p.Val36Leu), TOPMed rs1406945995, gnomAD rs1406945995, REVEL 0.05, CADD 6.93
- V36C (p.Val36Cys), gnomAD 12-109097781-TG-T, CADD 19.60
- V36M (p.Val36Met), gnomAD 12-109097785-G-A, REVEL 0.07, CADD 9.82
- V36V (p.Val36Val), gnomAD 12-109097787-G-A, CADD 1.24
- P37A (p.Pro37Ala), TOPMed rs918596003, gnomAD rs918596003, REVEL 0.03, CADD 0.40
- P37H (p.Pro37His), rs1205349419, ClinGen CA386468894, ClinVar RCV002027440, TOPMed rs1205349419, AlphaMissense 0.08, MetaLR 0.14, Uncertain significance, Hyper-IgM syndrome type 5
- P37L (p.Pro37Leu), TOPMed rs1205349419, gnomAD rs1205349419, REVEL 0.17, AlphaMissense 0.08, Uncertain significance
- P37T (p.Pro37Thr), gnomAD 12-109097788-C-A, REVEL 0.03, CADD 2.94
- E38D (p.Glu38Asp), TOPMed rs1442284730, gnomAD rs1442284730, REVEL 0.07, CADD 7.90, Uncertain significance, Hyper-IgM syndrome type 5
- E38K (p.Glu38Lys), gnomAD 12-109097791-G-A, REVEL 0.19, CADD 17.00
- E38* (p.Glu38Ter), gnomAD 12-109097791-G-T, CADD 35.00
- E39K (p.Glu39Lys), gnomAD 12-109097794-G-A, REVEL 0.09, CADD 14.80
- E39* (p.Glu39Ter), gnomAD 12-109097794-G-T, CADD 35.00
- S40N (p.Ser40Asn), TOPMed rs2042142425
- S40R (p.Ser40Arg), gnomAD 12-109097799-C-A, REVEL 0.09, CADD 10.80
Public UNG analysis runs
- UNG analysis run — UNG (618 variants) — completed 2026-08-20